Sarizotan in Parkinson Patients With L-dopa-induced Dyskinesia

• Status: Completed
• Trial end date: 2003-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The primary purpose of the study is to investigate the anti-dyskinetic effect of several doses of sarizotan in Parkinson patients in order to generate information on the dose-response relationship (dose-finding).

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: EMD Serono
• Treatments: Levodopa

Criteria

Inclusion Criteria:

• Male or Female

• The subject is an out-patient

• Age 30 years or above

• Dyskinesias present during more than 25% of the waking day

• Dyskinesias at least moderately disabling

• Written informed consent

Exclusion Criteria:

• Pregnancy and/or lactation

• Participation in another study within the last 30 days

• Dementia or other psychiatric illness that prevents provision of informed consent

• History of allergic disorders such as asthma

• Known hypersensitivity to the study treatment(s)

• Known hypersensitivity to ACTH